Goldman Sachs
RIGL icon

Goldman Sachs’s Rigel Pharmaceuticals RIGL Stock Holding History

Goldman Sachs’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-4,660
Closed -$133K – 6893
2013
Q4 		$133K Sell
4,660
-16,970
-78% -$498K ﹤0.01% 6164
2013
Q3 		$774K Buy
+21,630
New +$789K ﹤0.01% 4798

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's RIGL Position: Q1 2026 in Review

Goldman Sachs reduced its Rigel Pharmaceuticals (RIGL) stake by 35% in Q1 2026, selling an estimated $7.82M and leaving 439,101 shares worth $11.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2912.

Goldman Sachs first reported a position in RIGL in Q2 2013 and has held it in 51 quarters since. The position peaked at $28.8M in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Goldman Sachs held 439,101 shares of Rigel Pharmaceuticals worth $11.9M as of Q1 2026.
  • Goldman Sachs sold 232,777 Rigel Pharmaceuticals shares in Q1 2026, an estimated $7.82M.
  • Rigel Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2912 holding.
  • Goldman Sachs first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
  • Goldman Sachs's Rigel Pharmaceuticals position peaked at $28.8M in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.